Less than ideal: How oncologists practice with limited drug access

Journal of Oncology Practice

Volumn 8, Issue 3, 2012, Pages 190-195

  Chan, Kelvin K ^a   Wong, Bertha ^a   Siu, Lillian L ^a   Straus, Sharon E ^a   Chang, José ^a   Berry, Scott R ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ARTICLE; CANADA; CANCER PATIENT; CLINICAL PRACTICE; COLORECTAL CANCER; DRUG APPROVAL; DRUG FORMULARY; HEALTH CARE ACCESS; HUMAN; MEDICAL SPECIALIST; ONCOLOGIST; PATIENT CARE; SATISFACTION;

EID: 84867915756     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2011.000337     Document Type: Article

References (33)

1. Canadian Cancer Society: Canadian Cancer Statistics 2010. http://www.cancer.ca/canada-wide/about%20cancer/cancer%20statistics/ canadian%20cancer%20statistics.aspx.
2. American Cancer Society: Cancer Facts & Figures 2010. http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/ cancer-facts-and-figures-2010
3. Stillwell AP, Buettner PG, Ho YH: Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg 34:797-807, 2010
4. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000 (Pubitemid 30162806)
5. Fuchs CS, Marshall J, Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results from the BICC-C study. J Clin Oncol 26:689-690, 2008 (Pubitemid 351264373)
6. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000 (Pubitemid 30036347)
7. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
8. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
9. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004 (Pubitemid 41095110)
10. Tabernero J, Van Cutsem E, Díaz-Rubio E, et al: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25:5225-5232, 2007 (Pubitemid 350232254)
11. Jonker D, O'Callaghan C, Karapetis C, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040, 2007
12. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004 (Pubitemid 41079833)
13. Paris V, Docteur E: Pharmaceutical pricing and reimbursement policies in Canada: OECD Health Working Papers No. 24. http://ssrn.com/abstract=1329308
14. Menon D, Stafinski T, Stuart G: Access to drugs for cancer: Does where you live matter? Can J Public Health 96:454-8, 2005 (Pubitemid 41762922)
15. Khoo K, Colucci R, Hryniuk W, et al: Canada drug access part 3: The new wave of cancer drugs. CACC Report Card on Cancer in Canada 10:40-52, 2007
16. Health Canada: Avastin Summary Basis of Decision May 2006. http://www.hcsc.gc.ca/dhp-mps/prodpharma/sbd-smd/phase1-decision/drug-med/ sbd-smd-2006-avastin-089366-eng.php
17. Health Canada: Erbitux Summary Basis of Decision Jan 2007. http://www.hcsc.gc.ca/dhp-mps/prodpharma/sbd-smd/phase1-decision/drug-med/ sbd-smd-2007-erbitux-088225-eng.php
18. National Cancer Institute: Bevacizumab (Avastin) for Metastatic Colorectal Cancer. Jan 2005 update. http://www.cancer.gov/newscenter/ pressreleases/2003/bevacizumab
19. Jonker D, Maroun J, Spithoff K: Broad funding for oxaliplatin in Ontario (finally!). Curr Oncol 14:224-226, 2007
20. Nikolentzos A, Nolte E, Mays N: Paying for (Expensive) Drugs in the Statutory System: An Overview of Experiences in 13 Countries. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-089990
21. Flood CM, Hardcastle L: Tough choices: Private sale of drugs in public hospital. CMAJ 82:374-376, 2010
22. Cancer Care Ontario: Report of the Provincial Working Group on the Delivery of Oncology Medications for Private Payment in Ontario hospitals. Toronto, Ontario, Canada, Cancer Care Ontario. http://www.cancercare.on.ca/ common/pages/DownloadFile.aspx?itemid=13638
23. Berry SR, Hubay S, Soibelman H, et al: The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: A qualitative study. BMC Health Serv Res 7:193, 2007
24. Thomson J, Schofield P, Mileshkin L, et al: Do oncologists discuss expensive anticancer drugs with their patients? Ann Oncol 17:702-708, 2006
25. Jefford M, Tattersall MH: Informing and involving cancer patients in their own care. Lancet Oncol 3:629-637, 2002 (Pubitemid 35174681)
26. Schrag D, Hanger M: Medical oncologists' views on communicating with patients about chemotherapy costs: A pilot survey. J Clin Oncol 25:233-237, 2007 (Pubitemid 350003040)
27. Shepherd HL, Tattersall MH, Butow PN: Physician-identified factors affecting patient participation in reaching treatment decisions. J Clin Oncol 26:1724-1731, 2008
28. Mileshkin L, Schofield PE, Jefford M, et al: To tell or not to tell: The community wants to know about expensive anticancer drugs as a potential treatment option. J Clin Oncol 27:5830-5837, 2009
29. Jefford M, Savulescu J, Thomson J, et al: Medical paternalism and expensive unsubsidized drugs. BMJ 331:1075-1077, 2005 (Pubitemid 41597867)
30. Berry SR, Bell CM, Ubel PA, et al: Continental divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J Clin Oncol 28:4149-4153, 2010
31. Meropol NJ, Schrag D, Smith TJ, et al: American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 27:3868-3874, 2009
32. Richards M: Improving Access to Medicines for NHS Patients. London, England, Department of Health. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-089927
33. Peppercorn J, Burstein H, Miller FG, et al: Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol 26:5994-6000, 2008